Special Issue

Therapeutic Potential of Natural Plant-Derived Compounds in Glioblastoma and Other Brain Tumors

Message from the Guest Editors

Natural plant-derived compounds—such as flavonoids. alkaloids, terpenes, and polyphenols—have emerged as promising candidates for targeting glioblastoma and other brain tumors through diverse mechanisms, including induction of apoptosis, inhibition of proliferation, suppression of angiogenesis, and modulation of drug resistance pathways. Advances in nanoformulations and prodrug design are also enabling improved targeting and brain bioavailability of these compounds. For this Special Issue, we invite original research articles and reviews focusing on the role of plant-derived natural compounds in glioblastoma and other brain tumors. Relevant topics include mechanistic studies of phytochemicals that influence tumor signaling, resistance pathways, glioma stem cell plasticity, and therapeutic synergy with existing treatments. We also welcome research exploring pharmacokinetics, novel delivery systems for improved brain targeting, and the modulation of tumor metabolism and the tumor microenvironment by dietary or plantbased compounds.

Guest Editors

Dr. Agnieszka Nowacka

Dr. Ewa Aleksandra Ziółkowska

Dr. Daniela De Vita

Deadline for manuscript submissions

30 April 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/252137

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

